A phase I/II open label study of the safely and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis

Journal of Rheumatology

Volumn 23, Issue 8, 1996, Pages 1338-1344

  Kavanaugh, Arthur F ^a,c   Davis, Laurie S ^a   Jain, Rita I ^a   Nichols, Lisa A ^a   Norris, Steven H ^b   Lipsky, Peter E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adhesion receptors; Intercellular adhesion molecule 1; Monoclonal antibody; Rheumatoid arthritis

Indexed keywords

CORTICOSTEROID; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 0029739255     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Springer TA: Adhesion molecules of the immune system. Nature 1990;346:425-33.
2. Carlos TM, Harlan JM: Membrane proteins involved in phagocyte adherence to endothelium. Immunol Rev 1990;114:5-28.
3. Kavanaugh A, Lightfoot E, Lipsky P, Oppenheimer-Marks N: The role of CD11/CD18 in adhesion and transendothelial migration of T cells: Analysis utilizing CD18 deficient T cell clones. J Immunol 1991;146:4149-56.
4. Harris ED: Rheumatoid arthritis: Pathophysiology and implications for treatment. N Engl J Med 1990;322:1277-89.
5. Kavanaugh AF, Davis LS, Nichols LA, et al: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule-1 (ICAM-1). Arthritis Rheum 1994;37:922-9.
6. Davis LS, Kavanaugh AF, Nichols LA, Lipsky PE: The induction of persistent T cell hyporesponsiveness in vivo by a monoclonal antibody to ICAM-1 in rheumatoid arthritis patients. J Immunol 1995;154:3525-37.
7. Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS: Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. J Immunol 1995;155:5029-37.
8. Waldmann H, Cobbold S: The use of monoclonal antibodies to achieve immunological tolerance. Immunol Today 1993;14:247-51.
9. Arnett FC, Edworthy SM, Bloch DA, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
10. Haug CE, Colvin RB, Delmonico FL, et al: Phase I trial of immunosuppression with anti-ICAM-1 (CD54) Mab in renal allograft recipients. Transplantation 1993;55:766-73.
11. Paulus HE, Egger MJ, Ward JR, Williams JH, and the Cooperative Systematic Studies of Rheumatic Diseases Group: Analysis of improvement in individual rheumatoid arthritis patients treated with disease modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990;33:477-89.
12. Pincus T, Callahan LF, Brooks RH, Fuchs HA, Olsen NJ, Kaye JJ: Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. Ann Intern Med 1989;110:259-66.
13. Pinals RS, Masi AT, Larsen RA, and the Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-15.
14. Sewell KL, Trentham DE: Pathogenesis of rheumatoid arthritis. Lancet 1993;341:283-6.
15. Wacholtz MC, Patel SS, Lipsky PE: Leukocyte function-associated antigen 1 is an activation molecule for human T cells. J Exp Med 1989;170:431-48.
16. Felson D, Chernoff M, Wang M, Anderson J: Does duration of disease affect patient response to second-line drugs in rheumatoid arthritis? (abstr). Arthritis Rheum 1993;(suppl)36:S178.
17. Borg G, Allander E, Lund B, et al: Auranofin improves outcome in early rheumatoid arthritis: Results from a 2-year, double-blind placebo controlled study. J Rheumatol 1988;15:1747-54.
18. Chan K-W A, Felson DT, Yood RA, Walker AM: The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum 1994;37:814-20.
19. Jacoby RK, Jayson MIV, Cosh JA: Onset, early stages and prognosis of rheumatoid arthritis: A clinical study of 100 patients with 11 years follow-up. BMJ 1973;2:96-100.
20. van der Lubbe PA, Dijkmans BAC, Markusse HM, Nässander U, Breedveld FC: A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995;38:1097-106.
21. Olsen NJ, Cush JJ, Lipsky PE, et al: Multicenter trial of an anti-CD5 immunoconjugate in rheumatoid arthritis (abstr). Arthritis Rheum 1994;(suppl)37:S295.
22. Elliott MJ, Maini RN, Feldmann M, et al: Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
23. Koopman WJ, Gay S: Do nonimmunologically mediated pathways play a role in the pathogenesis of rheumatoid arthritis? Rheum Dis Clin North Am 1993;19:107-22.
24. Zvaifler NJ, Firestein GS: Pannus and pannocytes: Alternate models of joint destruction in rheumatoid arthritis. Arthritis Rheum 1994;37:783-9.
25. Cush JJ, Lipsky PE: Cellular basis for rheumatoid inflammation. Clin Orthop 1991;265:9-22.
26. Opdenakker G, van Damme J: Cytokine-regulated proteases in autoimmune diseases. Immunol Today 1994;15:103-7.
27. Almayi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET, Strom TB: Abrogation of glucocorticosteroid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-γ. J Immunol 1991;146:3523-7.